Securities code: Winsan(Chengdu) Medical Science And Technology Company Limited(600767) securities abbreviation: Winsan(Chengdu) Medical Science And Technology Company Limited(600767) Announcement No.: 2022006 Yunsheng (Chengdu) Medical Technology Co., Ltd
Announcement on receiving the inquiry letter from Shanghai Stock Exchange
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Yunsheng (Chengdu) Medical Technology Co., Ltd. (hereinafter referred to as “the company”) received the inquiry letter on matters related to Winsan(Chengdu) Medical Science And Technology Company Limited(600767) change of accounting firm (szgh [2022] No. 0196) (hereinafter referred to as “the inquiry letter”) from Shanghai Stock Exchange on March 22, 2022. The full text of the inquiry letter is as follows:
“On March 22, 2022, your company submitted an announcement that Rongcheng certified public accountants Co., Ltd. (hereinafter referred to as Rongcheng Office) could not meet the disclosure time requirements of the company’s annual report in 2021 due to the impact of the project and the epidemic, and plans to hire Beijing xingchanghua certified public accountants Co., Ltd. (hereinafter referred to as xingchanghua Office) It is the audit institution of the company’s 2021 annual financial report and internal control audit report. The company originally planned to disclose the annual report of 2021 on April 27, 2022. This change of annual audit accounting firm is only one month from the scheduled disclosure date of the annual report. In accordance with article 13.1.1 and other relevant provisions of the stock listing rules of the exchange, the following regulatory requirements are put forward for your company.
1、 The company and Rongcheng office are requested to fully verify and explain: (1) the specific contents and progress of the audit work carried out by Rongcheng office since it was hired as the company’s annual audit accounting firm, whether there are limited audit scope or other improper circumstances, the previous communication between the company’s management and Rongcheng office, and whether there are major differences between the two sides on matters related to the annual audit; (2) The specific reasons and rationality for the company to change the accounting firm today, and whether there are other reasons or known circumstances in advance that lead to the change of the accounting firm. Independent directors are invited to express clear opinions. 2、 The company and xingchanghua office are requested to fully verify and explain: (1) the specific communication process and content between the company and xingchanghua office on the audit matters of the annual report, whether xingchanghua office has fully communicated with Rongcheng office before accepting the appointment, and whether there are major differences between the two sides; (2) The specific contents, progress and follow-up arrangements of the annual audit work carried out by xingchanghua office, and whether there is a risk that the audit report cannot be issued on time. If so, please give full prompt.
3、 Please describe the assessment procedures and results adopted by the board of directors, independent directors and board of supervisors on the professional competence, integrity, ability to protect the legitimate rights and interests of investors, especially independence, and whether the relevant procedures are fully compliant and the conclusions are prudent and objective.
4、 The company shall properly arrange the annual report, promote the preparation and audit of the annual report according to the progress, and disclose the annual report on schedule. The annual audit accountant of the company shall reasonably arrange the audit work, strictly abide by the relevant contents of the accounting standards and audit standards, strictly perform the quality control review system, and issue appropriate audit conclusions.
Please disclose it to the public immediately after receiving this letter. Your company and all directors, supervisors, senior managers and relevant intermediaries shall be diligent and conscientious, attach great importance to and implement the requirements of this working letter, reply to our department in writing on the above issues within 5 working days, and fulfill the obligation of information disclosure as required. “
After receiving the inquiry letter, the company attaches great importance to it and will actively organize relevant parties to reply to the matters mentioned in the inquiry letter and fulfill the obligation of information disclosure in time. Please pay attention to investment risks.
It is hereby announced.
Board of directors of Yunsheng (Chengdu) Medical Technology Co., Ltd. March 23, 2022
